21.73 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||13.38 x 900|
|Ask||22.50 x 800|
|Day's Range||21.47 - 22.14|
|52 Week Range||16.26 - 23.95|
|Beta (3Y Monthly)||0.22|
|PE Ratio (TTM)||53.00|
|Earnings Date||Jul 14, 2017 - Jul 17, 2017|
|Forward Dividend & Yield||0.24 (1.14%)|
|1y Target Est||21.50|
Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.5 of its flagship machine learning modeling platform, ADMET Predictor®.
Simulations Plus (SLP) delivered earnings and revenue surprises of 20.00% and 4.59%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lancaster, California-based company said it had net income of 12 cents. The maker of software used in pharmaceutical research posted revenue of $8.5 million in the period. Simulations ...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put i...
Simulations Plus, Inc. (SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2019 fiscal year, the period ended February 28, 2019, on Tuesday, April 9, 2019. The Company will host a conference call on April 9, 2019, at 4:15 p.m. Eastern Time. Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions.
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! When Simulations Plus, Inc. (NASDAQ:SLP) released its most recent earningsRead More...
The oil and gas industry includes companies involved in the exploration, extraction, refining, transporting and marketing of oil and gas products. The oil and gas sector started 2018 off strong, coinciding with a rise in crude oil prices from around $50 to $70 per barrel.
Simulations Plus, Inc. (SLP) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Historically, Simulations Plus, Inc. (NASDAQ:SLP) has paid Read More...
DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded $1.5 million from Phase II of its previously announced Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The second phase of the grant funding will support DILIsym Services’ continued development, validation, and testing of its RENAsym software for predicting drug-induced kidney injury.
Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software, DDDPlus™. John DiBella, president of the Lancaster division, added: “The DDDPlus client base has steadily increased over the years, with several regulatory agencies now using the program to assess dissolution method and product specification questions.
DILIsym Services Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it is initiating development of IPFsym™, QSP (quantitative systems pharmacology) modeling software that will provide the ability to predict the efficacy of drugs being developed to treat idiopathic pulmonary fibrosis (IPF). The development of IPFsym is being sponsored by a large pharmaceutical company partner for $2.7 million, and it will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.
Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 21st Annual Needham Growth Conference in New York City on Wednesday, January 16, 2019, at 8:40 a.m. ET (5:40 a.m. PT). In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.
Simulations Plus (SLP) delivered earnings and revenue surprises of -18.18% and 1.15%, respectively, for the quarter ended November 2018. Do the numbers hold clues to what lies ahead for the stock?
The Lancaster, California-based company said it had profit of 9 cents per share. The maker of software used in pharmaceutical research posted revenue of $7.5 million in the period. Simulations Plus shares ...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
DILIsym Services Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released DILIsym® Version 8A, its flagship QST (quantitative systems toxicology) modeling software. Dr. Paul Watkins, chair of the DILI-sim Scientific Advisory Board, said: “The DILI-sim Initiative input has led to this release of an updated version of the DILIsym tool. DILIsym version 8A includes many new important example compounds and addresses, for the first time, drug-induced injury to bile duct cells.